Emeritus ProfessorJane Apperley

Jane Apperley qualified in Medicine from the University of Birmingham in 1979 and completed specialist training in haematology in Birmingham, London and Cambridge. Throughout this time she developed an interest in stem cell transplantation (SCT), and by default in chronic myeloid leukaemia (CML), which was the primary indication for SCT in the 1990s. She spent two years as a post-doctoral fellow at the Children’s Hospital in Boston, USA, training in gene transfer and therapy. She returned to the Hammersmith Hospital in 1993, was given a personal chair in Haemato-Oncology in 2002, and became the Clinical Director for Clinical Haematology at the Imperial College Healthcare NHS Trust, and the Chair of the Centre of Haematology at the Imperial College in 2003/4. She stepped down from both posts in 2021. In 2022 she was appointed to the position of Campus Director for the Hammersmith-White City Campus of Imperial College.

Professor Apperley has occupied international leadership positions including Presidencies of the British Society of Blood and Marrow Transplantation (BSBMT), the European Society of Blood and Marrow Transplantation (EBMT), the Center for International Blood and Marrow Transplant Research (CIBMTR) and the Joint Accreditation Committee of EISCT and EBMT (JACIE). She has reviewed national and international grant awards including acting as Chair of the European Research Council ‘Starting Investigators’ program.

Her interests remain the biology and management of CML, and her group at the Imperial College has extensive experience in the use of first, second and third generation tyrosine kinase inhibitors, particularly in the areas of molecular monitoring, mechanisms of drug resistance and adverse events. She has a long-standing interest in the impact of haematological diseases and their treatment on fertility, pregnancy and foetal outcome. She has been a member of the ELN CML Working Party since the creation of the ELN in 2004 and has been involved with the ELN Consensus Guidelines since the first recommendations in 2006, initially as the ‘expert’ in SCT but will now lead the next version of the guidelines, with a predicted publication date of 2024.